Publications by authors named "Miguel Regueiro"

Claim this Profile
R
Real-World Dose Escalation and Associated Direct Costs of Biologics in Management of Ulcerative Colitis: A Retrospective Database Study.
Miguel Regueiro, Tania Gulati, Ashmita Bandyopadhyay, Deborah A Fisher, Richard Moses

Dig Dis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative efficacy of immunomodulators, biologics, and advanced therapies for steroid-refractory acute severe ulcerative colitis: A network meta-analysis and time-to-event analysis.
Mohammad Al Hayek, Mohammed S Beshr, Mohamedhen Vall Nounou, Maria Manuela Estevinho, Maia Kayal, Miguel Regueiro

Dig Liver Dis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Practical Guide to Incorporating a Psychologist Into a Gastroenterology Practice.
Jessica K Salwen-Deremer, Sarah Ballou, Megan Petrik, Miguel Regueiro, Corey A Siegel

Gastroenterology· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An International Consensus on Appropriate Management of Corticosteroids in Clinical Trials in Inflammatory Bowel Disease.
Jurij Hanžel, Virginia Solitano, Sudheer Kumar Vuyyuru, Remo Panaccione, Bruce E Sands, Miguel D Regueiro

Gastroenterology· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natural History, Treatment Persistence and Predictors of Treatment Failure in Patients With Ulcerative Colitis on 5-Aminosalicylic Acid: A US Population-Level Cohort Study.
Gursimran S Kochhar, Himsikhar Khataniar, Jana G Hashash, Miguel Regueiro, Francis A Farraye

Inflamm Bowel Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First Real-World Evidence of an AI-Enhanced Digital Collaborative Care Model to Improve IBS Symptoms.
Stephen E Lupe, Joseph M Olson, Kendra Kamp, Margaret Heitkemper, Mythili P Pathipati, Miguel Regueiro

Neurogastroenterol Motil· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endoscopic Response to Subcutaneous Infliximab by Disease Location: A Post Hoc Analysis of the LIBERTY-CD Study.
Bruce E Sands, Stefan Schreiber, Marla C Dubinsky, Geert D'Haens, Bincy P Abraham, Miguel Regueiro

Clin Gastroenterol Hepatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety Outcomes in Patients With Ulcerative Colitis Using a Healthcare Administrative Database in the United States.
Miguel D Regueiro, Meenakshi Bewtra, Marla C Dubinsky, Diogo Branquinho, Chunyang Feng

Inflamm Bowel Dis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Efficacy of IL-12/23 and IL-23 Inhibitors for Induction and Maintenance Therapy in Moderate-to-Severe Crohn's Disease: A Systematic Review and Network Meta-Analysis.
Mohammad Al Hayek, Bisher Sawaf, Mohammed S Beshr, Ahmad Kassem, Dahham Alsoud, Miguel Regueiro

Inflamm Intest Dis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of upadacitinib maintenance therapy in patients with moderately to severely active Crohn's disease: 2-year results from the U-ENDURE Long-Term Extension study.
Edward V Loftus, Geert D'Haens, Edouard Louis, Miguel Regueiro, Vipul Jairath

J Crohns Colitis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Network Meta-Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's Disease.
Mohammad Shehab, Fatema Alrashed, Abdulrahman Alrashidi, Amro Hassan, Christopher Ma, Miguel Regueiro

Aliment Pharmacol Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reliability and Responsiveness of Endoscopic Indices for Assessing Crohn's Disease Postoperative Recurrence in the PREVENT trial.
Jurij Hanzel, Sudheer K Vuyyuru, Brian Bressler, Mark A Samaan, Malcolm Hogan, Miguel Regueiro

Clin Gastroenterol Hepatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Efficacy of Medical Therapies in Reducing the Risk of Postoperative Recurrence in Crohn's Disease: A Systematic Review and Network Meta-Analysis.
Mohammad Shehab, Omar Alrashed, Fatema Alrashed, Raghad Alyousefi, Amine Zoughlami, Miguel Regueiro

Inflamm Bowel Dis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic Acid.
Andres Yarur, Peter Irving, Britta Siegmund, Marla C Dubinsky, Ashwin N Ananthakrishnan, Miguel Regueiro

Inflamm Bowel Dis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancements in the prevention and management of postoperative Crohn's disease recurrence.
Shravya R Pothula, Miguel Regueiro, Benjamin H Click

Expert Rev Gastroenterol Hepatol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of mirikizumab treatment on fatigue in patients with moderately to severely active Crohn's disease: results from the phase 3 VIVID-1 study.
Miguel Regueiro, Monika Fischer, Peter Bossuyt, Marijana Protic, Kristina Traxler

J Crohns Colitis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upadacitinib Maintenance Therapy in Crohn's Disease: Final Results From the Randomized Phase 3 U-ENDURE Study.
Remo Panaccione, Miguel Regueiro, Scott D Lee, Raja Atreya, Gitte Pedersen

Clin Gastroenterol Hepatol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of glucagon-like peptide-1 receptor agonists on major adverse cardiovascular events in patients with inflammatory bowel disease.
Michael Saadeh, Apoorva Krishna Chandar, Sadeer Al-Kindi, Vu Quang Nguyen, Revital Gorodeski Baskin, Miguel Regueiro

Crohns Colitis 360· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A narrative literature review of the incidence and prevalence of safety outcomes in patients with ulcerative colitis.
Milena Gianfrancesco, Abiola Awofeso, Diogo Branquinho, Xiang Guo, Aoibhinn McDonnell, Miguel Regueiro

Expert Rev Gastroenterol Hepatol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-IL 12/23 versus Anti-Tumor Necrosis Factor-α in Patients with Biologically Naïve Crohn's Disease: A Systematic Review and Meta-analysis.
Mohammad Al Hayek, Bisher Sawaf, Shahem Abbarh, Yusuf Hallak, Muaz Alsabbagh Alchirazi, Miguel Regueiro

Inflamm Intest Dis· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Definitions, diagnosis, and management of postoperative recurrence in Crohn's disease patients with permanent ileostomy-a systematic review and meta-analysis.
Suha Abushamma, Tesfaye Yadete, Neil Nero, Katherine Falloon, Claire E Parker, Miguel Regueiro

J Crohns Colitis· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Racial Disparities in Utilization of Medications and Disease Outcomes in Inflammatory Bowel Disease Patients.
Khaled Alsabbagh Alchirazi, Osama Hamid, Thabet Qapaja, Mohammad Aldiabat, Nour Azzouz, Miguel Regueiro

Crohns Colitis 360· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical trials and young adults with inflammatory bowel disease.
Sneha Dave, Sydney Reed, Mara Shapiro, Yeabsira Taye, Isabela Hernandez, Miguel Regueiro

Health Care Transit· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential predictors of efficacy outcomes following tofacitinib dose reduction in patients with ulcerative colitis in stable remission: a post hoc analysis of outcomes from the RIVETING study.
Joana Torres, Geert R D'Haens, Miguel Regueiro, Genoile Santana, Julian Panés

Therap Adv Gastroenterol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Natural History of Inflammatory Bowel Disease in Adults With Common Variable Immunodeficiency: A Case Series From a Single US Tertiary Care Center.
Pankhuri Jha, Abbinaya Elangovan, Akash Keluth Chavan, Gregory Cooper, Jeffry Katz, Miguel Regueiro

Crohns Colitis 360· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis